Liv.52 DS Tablets
Evaluation of Liv.52 DS tablet as a hepatoprotective agent in prophylaxis with statin therapy
Dr. JKL Das Associate Professor, Department of Medicine, Patna Medical College, Patna, India. Dr. S.R. Prasad*, Medical Advisor, Dr. S.K. Mitra, Executive Director, R&D Center, The Himalaya Drug Company, Bangalore-562 123, India. *Corresponding author: Dr. S.R. Prasad, M.D, Medical Advisor, R&D Center, The Himalaya Drug Company, Bangalore, India. Phone : 91 080-2371 4444 Fax : 91 080-2371 4471 E-mail : dr.prasad@himalayahealthcare.com
CONCLUSION
There is a direct relationship between LDL and cardiovascular events, and many clinical trials have confirmed that lipid-lowering therapy reduces the risk of cardiovascular events. Statins have become one of the most commonly prescribed classes of lipid-lowering agents. However statin therapy is commonly associated with liver damage in terms of elevated transaminases. This study was conducted to evaluate Liv.52 DS tablet as a hepatoprotective agent in prophylaxis with statin.
The present clinical study observed that in the Atorvastatin alone group, there was a significant increase in the mean values of SGPT, SGOT and total bilirubin after 3 months, whereas no such increase in SGPT, SGOT and total bilirubin was observed in the group receiving Liv.52 DS tablet + Atorvastatin, after 3 months of therapy. There were no significant differences between the groups in terms of physical examination and subjective signs at the end of the treatment period. Hence, it may be concluded that Liv.52 DS tablet has hepatoprotective effect against statin-induced liver damage.
REFERENCES
1. Krukemyer, J.J., Talbert, R.L. Lovastatin: A new cholesterol-lowering agent. Pharmacotherapy 1987; 7: 198 210.
Hebert, P.R., Gaziano, J.M., Chan, K.S., et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA. 1997; 278: 313-321.
Vaziri, N.D., Liang, K. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am J Nephrol. 2004; 24: 606 613.
Steinmetz, K.L. Colesevelam hydrochloride. Am J Health Syst Pharm. 2002; 59: 932-939.
Asztalos, B.F., Horvath, K.V., McNamara, J.R., et al. Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis. 2002; 164: 361-369.
Pasternak, R.C., Smith, S.C. Jr., Bairey-Merz, C.N., et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of statin. Stroke. 2002; 33: 2337-2341.
Smith, C.C., Bernstein, L.I., Davis, R.B., et al. Screening for statin-related toxicity: the yield of transaminase and creatine kinase measurements in a primary care setting. Arch Intern Med. 2003; 163: 688-692.
Gotto, A.M. Jr. Safety and statin therapy: Reconsidering the risks and benefits. Arch Intern Med. 2003; 163: 657-659.
Farmer, J.A., Torre-Amione, G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 2000; 23: 197-213.
Anonymous. Integrated management of cardiovascular risk. Geneva: World Health Organization, 2002: pp. 1-36.
McKenney, J.M. New cholesterol guidelines, new treatment challenges. Pharmacotherapy 2002; 22: 853-863.
Hsu, I., Spinler, S.A., Johnson, N.E. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolmia. Ann Pharmacother. 1995; 29: 743-759.
Black, D.M. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscler Rep. 2002; 4: 34-41.
Bolego, C., Baetta, R., Bellosta, S., et al. Safety considerations for statins. Curr Opin Lipidol. 2002; 13: 637-644.
Sniderman, A.D. Is there value in liver function test and creatine phospokinase monitoring with statin use? Am J Cardiol. 2004; 94(Suppl.): 30F-34F.
Pfizer Inc. Lipitor (atorvastatin calcium) tablets package insert. Revised April 2002.
Bharani, A., Ganguly, A., Bhargava,
K.D. Salutary effect of Terminalia arjuna in patients with severe refractory heart failure. Int J Cardiol. 1995; 49: 91-99.
Tubaro, A., Del Negro, P., Ragazzi, E., et al. Anti-inflammatory and peripheral analgesic activity of esculetin in vivo. Pharmacol Res Commun. 1988; 20: 83-85.
Kim, J.H., Mun, Y.J., Woo, W.H., et al. Effects of the ethanol extract of Cichorium intybus on the
Refference: http://www.himalayahealthcare.com/pdf_files/liv263.pdf
Copyrights © 2009 healthyliver.co.uk